Dianthus Therapeutics, Inc. announced that Lei Meng, a current Class III Director, will not stand for reelection at the Annual Meeting.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.25 USD | -3.06% | +0.69% | +110.77% |
05-16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
05-10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+110.77% | 608M | |
+10.41% | 114B | |
+10.66% | 105B | |
-5.10% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-16.58% | 16.13B | |
+2.61% | 13.75B | |
+32.18% | 11.76B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc